FCMI
ORIC icon

Foresite Capital Management III’s Oric Pharmaceuticals ORIC Stock Holding History

Foresite Capital Management III’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-496,893
Closed -$16.8M – 12
2020
Q2 		$16.8M Buy
+496,893
New +$15.9M 14.9% 3

Other funds holding ORIC

PS
Peter Svennilson $1.23B AUM 301.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Foresite Capital Management III's ORIC Position: Q3 2020 in Review

Foresite Capital Management III sold out of Oric Pharmaceuticals (ORIC) in Q3 2020, closing a stake of 496,893 shares — an estimated $16.8M sold.

Foresite Capital Management III first reported a position in ORIC in Q2 2020 and held it in 1 quarter. The position peaked at $16.8M in Q2 2020. 54 funds tracked by Wall St. Rank hold ORIC as of Q3 2020.

  • Foresite Capital Management III reported no remaining Oric Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Foresite Capital Management III sold 496,893 Oric Pharmaceuticals shares in Q3 2020, an estimated $16.8M.
  • Foresite Capital Management III first reported a position in Oric Pharmaceuticals in Q2 2020 and held it in 1 quarter.
  • Foresite Capital Management III's Oric Pharmaceuticals position peaked at $16.8M in Q2 2020.
  • 54 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q3 2020.

Based on Foresite Capital Management III's 13F filing for Q3 2020, filed 13 Nov 2020.